Eli Lilly announced results from the Phase 3 TRIUMPH-1 trial, showing that its triple agonist retatrutide (12 mg) led to an average weight loss of 70.3 pounds (28.3%) over 80 weeks in adults with obesity or overweight with weight-related comorbidities. The trial included participants with a baseline BMI of 35 or higher.
Notably, 45.3% of participants achieved at least 30% weight loss, a level previously associated with bariatric surgery. The safety profile was consistent with the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects.
Retatrutide targets three receptors: GLP-1, GIP, and glucagon. The full results were presented at a medical conference and published in a peer-reviewed journal. Lilly plans to submit regulatory applications in 2026.
